UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high

Published on 10/16/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB revised Bimzelx potential above EUR 7 billion on October 5, 2026. UCB stock costs EUR 201.85 on October 16, 2026 below EUR 289.50.

Growth outlook and market valuation

UCB revised Bimzelx peak sales potential above EUR 7 billion on October 5, 2026.
First-half 2026 revenue rose 22 percent to EUR 4.27 billion.
UCB stock was trading at EUR 201.85 at 10:03 a.m. CEST at Lang & Schwarz on October 16, 2026.

Makroaufnahme eines dreidimensionalen Molekülmodells mit farbigen Kugeln vor unscharfem Laborhintergrund — UCB S.A. (BE0003739530) veranschaulicht durch scharfe Makroaufnahme einer dreidimensionalen Molekülstruktur im Forschungslabor, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 201.85 at Lang & Schwarz on October 16, 2026, at 10:03 a.m. CEST. The company's October 5 investor update put revised Bimzelx peak sales potential above EUR 7 billion, according to Quartr. The combination gives investors a clear measure of the commercial opportunity and the valuation already embedded in the stock.

EUR 7 billion drug opportunity

UCB's first-half 2026 revenue rose 22 percent to EUR 4.27 billion, while earnings before interest, taxes, depreciation and amortization increased 68 percent, according to the investor update dated October 5, 2026. Bimzelx had reached more than 148,000 patients worldwide, and the company had secured approval in more than 50 countries.

The investor update also reported that Bimzelx held about 35 percent of the global interleukin-17 psoriasis segment and nearly 50 percent in hidradenitis suppurativa. UCB's investor page lists Bimzelx sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7 billion, alongside more than 135,000 patients globally.

Three milestones shaped the story

On September 23, 2026, UCB discussed first-half revenue of EUR 4.27 billion and upgraded guidance at the Bank of America Global Healthcare Conference, as reported by Investing.com. On September 29, 2026, UCB presented new Bimzelx, Zilbrysq and Rystiggo data. On October 5, 2026, the company set revised Bimzelx peak sales potential above EUR 7 billion in its investor update.

Which dates matter next?

UCB's pipeline lists topline results for STACCATO alprazolam in the fourth quarter of 2026 or first half of 2027, while bimekizumab hidradenitis suppurativa results are scheduled for the first half of 2027, according to UCB.

Valuation stays below the yearly high

UCB stock remains below its EUR 289.50 52-week high and above its EUR 197.45 low, based on the October 15, 2026 market snapshot. The EUR 39.1 billion market capitalization puts the commercial execution of Bimzelx at the center of the investment case, while pipeline readouts provide the next company-specific milestones.

UCB was trading at EUR 201.85 at Lang & Schwarz on October 16, 2026, at 10:03 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of UCB stock.